VEGFA and neoplasm: Although they did not affect the number of macrophages, key drivers of tumor angiogenesis, (Fig. 3C and Supplementary Figure 2), both LCL-SIM and LCL-SIM-DMXAA therapies strongly suppressed the most powerful pro-angiogenic protein VEGF (with more than 55% and 95% respectively, compared to its control level, Fig. 3A and Table 3) and significantly reduced the density of blood vessels compared to their density in control tumor tissue (Fig. 3B, P < 0.05).